Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Oncol. 2022 Jun;61(6):757-763. doi: 10.1080/0284186X.2022.2066985. Epub 2022 Apr 29.
Brain metastasis (BM) are uncommon among women with epithelial ovarian cancer (EOC). The frequency, risk factors and clinical repercussions of BM in these patients are not well described.
We retrospectively evaluated EOC patients treated at our center from 2002 to 2020 and assessed their clinical parameters, risk for BM development and association with overall survival (OS). This cohort has a known high frequency of BRCA mutation carriers () due to women of Ashkenazi Jewish descent.
Among 1035 EOC patients, 29 (2.8%) were diagnosed with BM. The prevalence of mutations was more common among women with BM (56.5% vs. 34.3%, = 0.033). The BM rate in patients with was higher than the BM rate in those with wildtype BRCA (; 5.1% vs. 2.1%, OR = 2.6; 95% CI: 1.2-5.4, = 0.013). Median time from diagnosis to BM and from disease recurrence to BM was longer among patients with . Median OS was not significantly different among patients with BM versus those without BM (59.4 vs. 73.4 months, = 0.243). After BM diagnosis, median OS was not statistically significantly different between patients with and those with (20.6 vs. 12.3 months, = 0.441). Treatment with poly (ADP-ribose) polymerase inhibitors and bevacizumab had no impact on subsequent development of BM.
BM are rare among EOC patients. However, the risk is three-fold higher among patients with . BM do not significantly alter OS among EOC patients. The higher rate of BM in patients with may be related to longer OS in this subpopulation.
脑转移（BM）在女性上皮性卵巢癌（EOC）中并不常见。这些患者中 BM 的频率、危险因素和临床影响尚不清楚。
我们回顾性评估了 2002 年至 2020 年在我们中心治疗的 EOC 患者，并评估了他们的临床参数、BM 发生风险以及与总生存期（OS）的关系。由于这些患者的祖先多为阿什肯纳兹犹太人，因此该队列中 BRCA 突变携带者的频率较高。
在 1035 名 EOC 患者中，有 29 名（2.8%）被诊断为 BM。BM 患者中 突变的发生率高于野生型 BRCA 患者（56.5%比 34.3%，=0.033）。 突变患者的 BM 发生率高于野生型 BRCA 患者（5.1%比 2.1%，OR=2.6；95%CI：1.2-5.4，=0.013）。 患者从诊断到 BM 以及从疾病复发到 BM 的中位时间更长。BM 患者与无 BM 患者的中位 OS 无显著差异（59.4 与 73.4 个月，=0.243）。在 BM 诊断后， 患者与 患者的中位 OS 无统计学差异（20.6 与 12.3 个月，=0.441）。聚（ADP-核糖）聚合酶抑制剂和贝伐单抗的治疗对随后 BM 的发展没有影响。
BM 在 EOC 患者中罕见。然而， 患者的风险是其三倍。BM 不会显著改变 EOC 患者的 OS。 患者中 BM 发生率较高可能与该亚群的 OS 延长有关。
